标题:Disrupting Acetyl-lysine Interactions: Recent Advance in the Development of BET Inhibitors
作者:Zhang, Fa; Ma, Shutao
作者机构:[Zhang, Fa; Ma, Shutao] Shandong Univ, Sch Pharmaceut Sci, Dept Med Chem, Key Lab Chem Biol,Minist Educ, 44 West Culture Rd, Jinan 250012, Shandong, P 更多
通讯作者:Ma, ST
通讯作者地址:[Ma, ST]Shandong Univ, Sch Pharmaceut Sci, Dept Med Chem, 44 West Culture Rd, Jinan 250012, Shandong, Peoples R China.
来源:CURRENT DRUG TARGETS
出版年:2018
卷:19
期:10
页码:1148-1165
DOI:10.2174/1389450119666171129165427
关键词:BET inhibitors; acetyl-lysine; transcriptional regulation; chromatin;; BRDs; SARs
摘要:Background: Histone acetylation is an essential approach of post-translational modification (PTM) and a significant component of epigenetic regulation that is mediated by Bromodomains-containing protein (BRDs). In recent years, many researchers have found that a variety of malignancy, inflammatory and other diseases occurrences and developments are associated with BRD4 expression disorders or dysfunction. Meanwhile, many inhibitors of the extra-terminal (BET) family have been reported in many papers.; Objective: This review summarized those newly found BET inhibitors, their mechanism of action and bioactivity. Secondly, those compounds were mainly classified based on their structures and their structure-activity relationship information was discussed. Beyond that, every compound's design strategy was pointed out.; Results and Conclusion: Herein, the recent advances reported were reviewed for discovering more excellent small molecule inhibitors. Currently, in addition to compound 4, compounds 7, 22 and 90, have also been into the clinical trial stage. In the view of the outstanding performance of BET inhibitors in anti-tumor, anti-inflammatory and anti-drug resistance, we believe that more and more BET inhibitors will become the new epigenetic therapy for cancer, inflammation and autoimmune disease in clinical practice in the near future.
收录类别:SCOPUS;SCIE
资源类型:期刊论文
原文链接:https://www.scopus.com/inward/record.uri?eid=2-s2.0-85049923688&doi=10.2174%2f1389450119666171129165427&partnerID=40&md5=7f06e5912d8e70f84bc015f920e00afd
TOP